Biomarkers, particularly molecular biomarkers, are key indicators of biological processes in normal or diseased conditions. Recent research on their role in pathogenesis, coupled with the advancement of laboratory technology, has allowed for the objective measurement of biomarkers at a cellular level. This increase in research on molecular biomarkers has yielded more information for clinical investigators to properly assess disease diagnosis, prognosis, treatment, and management. Since 2003, the FDA has approved 139 tests for biomarkers.
microRNA In Situ Hybridization (miRNA ISH) :
Among the various molecular biomarkers, microRNAs (miRNAs) are a recent addition to the diagnostic toolkit for the cancer clinicians. MiRNAs are remarkably stable and are well preserved due to their very short sequences and resistance to endogenous enzymes. Unlike the traditional method of assessing miRNA by total RNA extraction followed by qRT-PCR or microarray techniques, utilizing in situ hybridization in formalin-fixed paraffin-embedded tissues (FFPE) reduces the loss of spatial context caused by tissue lysing.
In situ hybridization in formalin-fixed paraffin-embedded tissues (FFPE) as well as fresh snap frozen specimens allows the detection and localization of definitive nucleic acid sequences within a cell or tissue. High specificity is ensured through the action of the complementary nucleic acid binding sequence.
The miRNA expression profiles are used to assess the cancer type or conditions like:
- Cancer of unknown primary
- Undifferentiated and poorly differentiated tumors
- Classification of cancer subtypes
- Grading and staging of cancer
BioGenex Super Sensitive Nucleic Acid (SSNA) miRNA Probes:
BioGenex has developed proprietary Super Sensitive Nucleic Acid (SSNA) miRNA probes that are specially designed to enhance signals from the intrinsically low populated miRNAs. These probes have high melting temperatures enabling stringent washes at elevated temperatures to remove non-specific binding. BioGenex miRNA probes are dual-end labeled with a fluorophore that amplifies the signal, giving intense stains. BioGenex SSNA microRNA probes combined with visualization system allows the visualization of target miRNAs in specific cells in the spatial context and aid in studying the lowly expressed miRNA populations to assess the physiological function of miRNA.
We also support a one-stop solution for all miRNA related research including automated instruments, probes, nucleic acid retrievals, detection systems, and ancillaries.
Refer our Biomarker Panel section for a collection of articles that uses our SSNA probes to address key challenges in cancer research and presented with initial validation studies.
Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma Differentiation by New miRNA Biomarker Panel
Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma Differentiation by New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CC) are two highly...
Squamous Cell Carcinoma Differentiation of Cervical Cancer using New miRNA Biomarker Panel
Squamous Cell Carcinoma Differentiation of Cervical Cancer using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Cervical cancer is one of the most common malignant tumors of the female reproductive tract. It is the...
Glioma Prognostic Subtyping – Astrocytoma, Oligodendroglioma, Meningioma, and Glioblastoma using New miRNA Biomarker Panel
Glioma Prognostic Subtyping - Astrocytoma, Oligodendroglioma, Meningioma, and Glioblastoma using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Malignant gliomas are extremely aggressive and lethal form of brain...
Biomarker Panel for Differentiation of Wild Type and Breast Cancer Susceptibility Gene (BRCA) Mutated Breast Cancer
Biomarker Panel for Differentiation of Wild Type and Breast Cancer Susceptibility Gene (BRCA) Mutated Breast Cancer miRNA SSNA in situ Hybridization System Breast cancer represents a heterogeneous group of tumors characterized by a wide range of clinical, pathologic...
Wild Type and Mutated BRCA – Differentiation of Breast Cancer using New miRNA Biomarker Panel
Wild Type and Mutated BRCA - Differentiation of Breast Cancer using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Breast cancer represents a heterogeneous group of tumors characterized by a wide range of clinical,...
Squamous Cell Carcinoma (SCC) and Adenocarcinoma (AD) Differentiation in Non-Small Cell Lung Cancer (NSCLC) using New miRNA Biomarker Panel
Squamous Cell Carcinoma (SCC) and Adenocarcinoma (AD) Differentiation in Non-Small Cell Lung Cancer (NSCLC) using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Lung cancer represents a heterogeneous group of tumors...
Triple Negative Breast Cancer – Differentiation of TNBC (ER-, PR-, and HER2/neu-) using New miRNA Biomarker Panel
Triple Negative Breast Cancer - Differentiation of TNBC (ER-, PR-, and HER2/neu-) using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA in situ hybridization (ISH) kit Like many cancers, breast cancers are highly diverse with a range of distinct...
Prostate Cancer (PC) and Benign Prostatic Hyperplasia (BPH) Differentiation by New miRNA Biomarker Panel
Prostate Cancer (PC) and Benign Prostatic Hyperplasia (BPH) Differentiation by New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Prostate cancer and benign prostatic hyperplasia (BPH) are the most frequent and deadly...
Glioma Prognostic Subtyping
Renal Cell Carcinoma (RCC) Classification - ccRCC, pRCC, and chRCC using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Renal cell carcinoma (RCC) consists of an array of morphologically and genetically distinct...
Renal Cell Carcinoma (RCC) Classification
Renal Cell Carcinoma (RCC) Classification - ccRCC, pRCC, and chRCC using New miRNA Biomarker Panel Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit Renal cell carcinoma (RCC) consists of an array of morphologically and genetically distinct...